Nov 10 (Reuters) - Spark Therapeutics Inc:

ADVERTISEMENT

* Three-Year follow-up phase 3 data provide additional information on efficacy, durability and safety of investigational Luxturna(voretigene neparvovec) in patients with biallelic RPE65-mediated inherited retinal disease Source text for Eikon: Further company coverage: